CytomX Therapeutics, Inc.

CTMX

CIK 0001501989 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$663K
↓-98.3% -$37Mvs FY2024 (Q4)
Gross Profit
$663K
↓-98.3% -$37Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Weak
38/100
  • Profitability
    0ROIC -35.9% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 3.09 (above 1.5 = solid)
  • Leverage
    100D/E -0.02 (under 0.5 = conservative)
  • Efficiency
    28Asset Turnover 0.56x (1.0+ = capital-efficient)
  • Growth
    0Revenue YoY -98.3% (10% = solid, 25%+ = elite)
  • Margin Trend
    0Op Margin -264.4% · trend -88.9pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$347K
investment in PP&E
Stock-based comp (TTM)
$6M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$152M
everything owned
Total liabilities
$53M
everything owed
Stockholders' equity
$99M
shareholder claim
Net debt
$-11M
Net cash position ($11M)

Recent performance · 49 quarters

Revenue↓-98.3% -$37M
$663K
Net Income↓-348.1% -$20M
$-14M
Free Cash Flow↓-151.3% -$121K
$-201K
Operating Margin↓-276.7pts
-264.4%

Drill down